These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 30499237

  • 1. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J.
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [Abstract] [Full Text] [Related]

  • 2. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N.
    Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
    [Abstract] [Full Text] [Related]

  • 3. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK, Giri R, Shembalkar JV, Gupta SK, Mohan B, Kurmi P, Kumar SR, Sawardekar VM, Mishra A, Murthy LS, Arya VV, Sonawane AR, Soni PN, Gofne SK, Karnawat SR, Rajurkar MN, Patel PM, Lakhwani LK, Mehta SC, Joglekar SJ.
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Frias JP, Gonzalez-Galvez G, Johnsson E, Maaske J, Testa MA, Simonson DC, Dronamraju N, Garcia-Sanchez R, Peters AL.
    Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
    Frías JP, Maaske J, Suchower L, Johansson L, Hockings PD, Iqbal N, Wilding JPH.
    Diabetes Obes Metab; 2022 Jan; 24(1):61-71. PubMed ID: 34514692
    [Abstract] [Full Text] [Related]

  • 6. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N.
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [Abstract] [Full Text] [Related]

  • 7. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T, Ekholm E, Johnsson E, Dronamraju N, Jabbour S, Lind M.
    Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
    Vilsbøll T, Ekholm E, Johnsson E, Garcia-Sanchez R, Dronamraju N, Jabbour SA, Lind M.
    Diabetes Obes Metab; 2020 Jun; 22(6):957-968. PubMed ID: 32003150
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J, Perl S, Johnsson E, García-Sánchez R, Jacob S.
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.
    Kim NH, Moon JS, Lee YH, Cho HC, Kwak SH, Lim S, Moon MK, Kim DL, Kim TH, Ko E, Lee J, Kim SG.
    Diabetes Obes Metab; 2024 Sep; 26(9):3642-3652. PubMed ID: 38853720
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 18. Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study.
    Han KA, Hwang YC, Moon SJ, Cho HC, Yoo HJ, Choi SH, Chon S, Kim KA, Kim TN, Kang JG, Park CY, Won JC, Cho E, Kim J, Park KS.
    Diabetes Obes Metab; 2024 Sep; 26(9):3743-3752. PubMed ID: 38978173
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.